BAIT
ANXA1
ANX1, LPC1, RP11-71A24.1
annexin A1
GO Process (12)
GO Function (8)
GO Component (11)
Gene Ontology Biological Process
- alpha-beta T cell differentiation [ISS]
- cellular component movement [TAS]
- cellular response to glucocorticoid stimulus [IDA]
- inflammatory response [TAS]
- keratinocyte differentiation [IDA]
- negative regulation of apoptotic process [TAS]
- negative regulation of interleukin-8 secretion [IMP]
- neutrophil clearance [IMP]
- neutrophil homeostasis [IMP]
- peptide cross-linking [IDA]
- positive regulation of vesicle fusion [IDA]
- signal transduction [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
LMNA
CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL, FPLD, FPLD2, HGPS, IDC, LDP1, LFP, LGMD1B, LMN1, LMNC, LMNL1, PRO1, RP11-54H19.1
lamin A/C
GO Process (14)
GO Function (2)
GO Component (9)
Gene Ontology Biological Process
- activation of signaling protein activity involved in unfolded protein response [TAS]
- apoptotic process [TAS]
- cellular component disassembly involved in execution phase of apoptosis [TAS]
- cellular protein metabolic process [TAS]
- cellular response to hypoxia [IEP]
- endoplasmic reticulum unfolded protein response [TAS]
- establishment or maintenance of microtubule cytoskeleton polarity [ISS]
- mitotic cell cycle [TAS]
- mitotic nuclear envelope disassembly [TAS]
- mitotic nuclear envelope reassembly [TAS]
- muscle organ development [IMP]
- positive regulation of cell aging [IDA]
- protein localization to nucleus [ISS]
- regulation of cell migration [ISS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Protein-peptide
An interaction is detected between a protein and a peptide derived from an interaction partner. This includes phage display experiments.
Publication
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Immune checkpoint inhibitors (ICIs) therapy targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) shows promising clinical benefits. However, the relatively low response rate highlights the need to develop an alternative strategy to target PD-1/PD-L1 immune checkpoint. Our study focuses on the role and mechanism of annexin A1 (ANXA1)-derived peptide A11 degrading PD-L1 and the effect of A11 ... [more]
J Immunother Cancer Mar. 01, 2023; 11(3); [Pubmed: 37001908]
Throughput
- High Throughput
Curated By
- BioGRID